These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 22421765)

  • 41. Capecitabine-induced diffuse palmoplantar keratoderma: is it a sequential event of hand-foot syndrome?
    Do JE; Kim YC
    Clin Exp Dermatol; 2007 Sep; 32(5):519-21. PubMed ID: 17509060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Capecitabine-based chemoradiotherapy with adjuvant capecitabine for locally advanced squamous carcinoma of the uterine cervix: phase II results.
    Domingo E; Lorvidhaya V; de Los Reyes R; Syortin T; Kamnerdsupaphon P; Lertbutsayanukul C; Vito-Cruz E; Tharavichitkul E; Jin K; Yoshihara M; Cupino N; Lertsanguansinchai P
    Oncologist; 2009 Aug; 14(8):828-34. PubMed ID: 19661184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Management of hand-foot syndrome in patient treated with capecitabine].
    Fujii C; Anami S; Fujino M; Yasui Y; Fujita M; Inoue M; Nakayama T; Kamigaki S; Tatsuta M; Furukawa H
    Gan To Kagaku Ryoho; 2008 Aug; 35(8):1357-60. PubMed ID: 18701848
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
    Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
    Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
    [TBL] [Abstract][Full Text] [Related]  

  • 45. How the new oral antineoplastics affect nursing practice: capecitabine serves to illustrate.
    Szetela AB; Gibson DE
    Am J Nurs; 2007 Dec; 107(12):40-8; quiz 48-9. PubMed ID: 18049060
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Kim CA; Spratlin JL; Armstrong DE; Ghosh S; Mulder KE
    Clin Colorectal Cancer; 2014 Sep; 13(3):199-206. PubMed ID: 25088184
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an oncopaz cooperative group study.
    Feliu J; Escudero P; Llosa F; Bolaños M; Vicent JM; Yubero A; Sanz-Lacalle JJ; Lopez R; Lopez-Gómez L; Casado E; Gómez-Reina MJ; González-Baron M
    J Clin Oncol; 2005 May; 23(13):3104-11. PubMed ID: 15860870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preplanned safety analysis of the JFMC37-0801 trial: a randomized phase III study of six months versus twelve months of capecitabine as adjuvant chemotherapy for stage III colon cancer.
    Suto T; Ishiguro M; Hamada C; Kunieda K; Masuko H; Kondo K; Ishida H; Nishimura G; Sasaki K; Morita T; Hazama S; Maeda K; Mishima H; Ike H; Sadahiro S; Sugihara K; Okajima M; Saji S; Sakamoto J; Tomita N
    Int J Clin Oncol; 2017 Jun; 22(3):494-504. PubMed ID: 28078540
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous oral capecitabine at fixed dose in patients older than 75 years with metastatic colorectal and gastric cancer: a study of the Multidisciplinary Oncology Group on Gastrointestinal Tumors.
    Petrioli R; Pascucci A; Francini E; Marsili S; Fiaschi AI; Civitelli S; Tanzini G; Battistelli S; Lorenzi M; Roviello F; Francini G;
    Anticancer Drugs; 2008 Jan; 19(1):91-6. PubMed ID: 18043134
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Initial report of KSCC0803: feasibility study of capecitabine as adjuvant chemotherapy for stage III colon cancer in Japanese patients.
    Emi Y; Kakeji Y; Oki E; Saeki H; Ando K; Kitazono M; Sakaguchi Y; Morita M; Samura H; Ogata Y; Akagi Y; Natsugoe S; Shirouzu K; Tokunaga S; Sirzen F; Maehara Y;
    Int J Clin Oncol; 2013 Apr; 18(2):254-9. PubMed ID: 22240888
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Preoperative capecitabine with pelvic radiotherapy for locally advanced rectal cancer (phase I trial).
    Veerasarn V; Phromratanapongse P; Lorvidhaya V; Lertsanguansinchai P; Lertbutsayanukul C; Panichevaluk A; Boonnuch W; Chinswangwatanakul V; Lohsiriwat D; Rojanasakul A; Thavichaigarn P; Jivapaisarnpong P
    J Med Assoc Thai; 2006 Nov; 89(11):1874-84. PubMed ID: 17205868
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quality of life under capecitabine (Xeloda®) in patients with metastatic breast cancer: data from a german non-interventional surveillance study.
    Müller V; Fuxius S; Steffens CC; Lerchenmüller C; Luhn B; Vehling-Kaiser U; Hurst U; Hahn LJ; Soeling U; Wohlfarth T; Zaiss M
    Oncol Res Treat; 2014; 37(12):748-55. PubMed ID: 25531721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Seol YM; Song MK; Choi YJ; Kim GH; Shin HJ; Song GA; Chung JS; Cho GJ
    Jpn J Clin Oncol; 2009 Jan; 39(1):43-8. PubMed ID: 18997184
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: a randomized controlled trial.
    Xia Y; Qiu Y; Li J; Shi L; Wang K; Xi T; Shen F; Yan Z; Wu M
    Ann Surg Oncol; 2010 Dec; 17(12):3137-44. PubMed ID: 20602260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
    Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
    Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study.
    Kang YK; Lee SS; Yoon DH; Lee SY; Chun YJ; Kim MS; Ryu MH; Chang HM; Lee JL; Kim TW
    J Clin Oncol; 2010 Aug; 28(24):3824-9. PubMed ID: 20625131
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [First-line Xeloda (Capecitabine) treatment for advanced and recurrent colorectal cancer].
    Guan ZZ; Liu DG; Yu BM; Wu WQ; Shi D; Zhao Y; Wei YQ; Zou LQ; Wu XD; Zhuang W; Feng FY; Zhang P; Yu SY; Xiong HH; Fu Q; Zheng S; Huang JJ; Wu G; Yang CY; Sun SR; Ruan QL
    Zhonghua Zhong Liu Za Zhi; 2004 Feb; 26(2):119-21. PubMed ID: 15059335
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Preoperative chemoradiation for locally advanced rectal cancer with capecitabine 2,000 mg/m2/day.
    Veerasarn V; Boonnuch W; Chinswangwatanakul V; Lohsiriwat D; Mahamadsolaeh P
    J Med Assoc Thai; 2008 Oct; 91(10):1583-8. PubMed ID: 18972903
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Breast cancer and the hand-foot syndrome].
    Llambrich C; Falcou MC; De Rycke Y; Cottu P; Carrié S; Medjbari M
    Soins; 2012 Jun; (766):25-8. PubMed ID: 22870762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hypertriglyceridaemia-induced pancreatitis: a contributory role of capecitabine?
    Chan HY; Ng CM; Tiu SC; Chan AO; Shek CC
    Hong Kong Med J; 2012 Dec; 18(6):526-9. PubMed ID: 23223655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.